<DOC>
	<DOCNO>NCT00512863</DOCNO>
	<brief_summary>To evaluate efficacy SC injection 3 regimen adalimumab vs. placebo change post-bronchodilator FEV1 Baseline Week 16 use treatment refractory asthma .</brief_summary>
	<brief_title>A Dose-Finding Study Evaluate Safety , Efficacy Pharmacokinetics Adalimumab Subjects With Refractory Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Documented history refractory asthma , define American Thoracic Society,31 define 1 major least 2 minor criterion Actual document history reversible airway obstruction Baseline FEV1 40 % − 80 % predict height , age , sex Screening , demonstrate 6 hour shortacting agonist and/or 24 hour longacting agonist History least 1 asthma exacerbation lead oral , IV IM corticosteroid ER/Urgent Care Center visit hospitalization within past year prior Screening . This asthma exacerbation within 30 day prior Screening Adequate cardiac , renal hepatic function determine principal investigator demonstrate Screening laboratory evaluation , questionnaire , physical examination result within normal limit Subjects must able selfinject study medication designee healthcare professional inject study medication Active lung disease ( e.g. , bronchitis , chronic obstructive pulmonary disease [ COPD ] , interstitial lung disease , pulmonary fibrosis ) asthma Current treatment corticosteroidresistant asthma ( e.g. , methotrexate [ MTX ] , cyclosporine , gold salt , troleandomycin , immune globulin intravenous [ IGIV ] , mycophenolate mofetil ) History cancer lymphoproliferative disease successfully completely treat cutaneous squamous cell basal cell carcinoma carcinoma − insitu cervix . History listeria , human immunodeficiency virus ( HIV ) , chronic active Hepatitis B , immunodeficiency syndrome , central nervous system ( CNS ) demyelinate disease active TB Females pregnant discontinue breastfeeding . Subject history clinically significant drug alcohol abuse last year Subjects poorly control medical condition . Abnormal , clinically significant screen laboratory analysis ( include ECG ) . Subjects prior exposure Tysabri® ( natalizumab ) Prior treatment TNF antagonist , include adalimumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>